Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome
- 1 November 2001
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (9) , 873-878
- https://doi.org/10.1038/sj.bmt.1703252
Abstract
Candidemia is a serious complication in patients following allogeneic blood, marrow, and organ transplantation. Fourteen patients developed nosocomial fungemia among 204 allogeneic marrow transplants performed during 1997-1999. Incidence of hematogenous candidiasis was 6.8 per 100 allogeneic BMT. All 14 had an indwelling central venous catheter (CVC) and fluconazole (100-200 mg daily) was given prophylactically. In 11 (78.5%) neutropenic patients, duration between agranulocytosis and diagnosis of fungemia was (median, +/- s.d.) 10 +/- 8 days. Candida glabrata (53.3%) was the most common yeast species, followed by C. krusei (33.3%), and C. parapsilosis (13.3%). Candida albicans was conspicuously absent. Ten patients (71.4%) had primary transplant-related complication (>2 days) including hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) (n = 5), severe hemorrhagic cystitis (n = 3), and bacteremia (n = 2). Seven (50.0%) patients expired and in three (21.4%) deaths were attributed to fungemia. The impact of a primary transplant-related complication on short-term survival in this setting was not significant (P = 0.07) (HUS/TTP (P > 0.5); neutropenia (P > 0.5); GVHD (P = 0.35)). Removal of CVC did not alter outcome in our group (P > or = 0.5) although in patients with persistent fungemia (>72 h), and those with preceding bacteremia, mortality was significantly higher (P = 0.002). Conventional prognosticators of poor outcome did not adversely effect short-term survival in our transplant recipients with hematogenous candidiasis. The predominance of C. glabrata and C. krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen.Keywords
This publication has 28 references indexed in Scilit:
- Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough CandidemiaClinical Infectious Diseases, 2001
- Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)Clinical Infectious Diseases, 1999
- Retrospective analysis of yeast colonization and infections in paediatric bone marrow transplant recipientsMycoses, 1997
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- Efficacy and Safety of Fluconazole Prophylaxis for Fungal Infections after Marrow Transplantation--A Prospective, Randomized, Double-Blind StudyThe Journal of Infectious Diseases, 1995
- The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patientsJournal of Antimicrobial Chemotherapy, 1994
- Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patientsAntimicrobial Agents and Chemotherapy, 1993
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with FluconazoleNew England Journal of Medicine, 1991
- Fungemia in the immunocompromised hostThe American Journal of Medicine, 1981